The challenges of project management in the pharmaceutical industry

In the business of pharmaceutical companies, with more uncertainties related to the method of a research project, project management becomes more difficult. Project management within the pharmaceutical business involves:

  1. Perimeter management
  2. Upcoming project, run and monitor
  3. Future schedule and budget and management
  4. Stakeholder management
  5. Management of regulatory and compliance pathways
  6. Environmental Safety
  7. Risk management
  8. Team management

Challenges underlie each of these aspects of project management. The interdependencies between these components create even more breakthroughs. While the developed product is also effective for the supposed use, it is going to need hazardous chemicals and ingredients in the production method. Any deviation from safety plans will cause long delays in the project schedule.

Although changes are inevitable, it is natural that stakeholders may, internally or externally, resist the implementation of an amendment. Making an associate in a nursing atmosphere that embraces amendment is essential in stakeholder management. The project manager must regularly evolve his approach to stakeholder management. Improving soft skills for effective communication is as vital as improving listening skills. A “no surprises” policy and open communication are helpful in preventing the delivery of incorrect information.

Recently, other industries have moved to a matrix organization, in a higher matrix organization, there are four key players in project management: the project manager, determined managers, senior management and team members. project team.

Although each of these parties has its role and responsibilities, interdependencies become inevitable. The square measure of the project manager challenged to keep this relationship viable for the benefit of the project. In addition, project managers within the pharmaceutical business encounter challenges in the following areas:

  1. Resource limitation
  2. Cross-functional team management
  3. Settlement process
  4. Cultural variations
  5. Customer management

With pressures to reduce prices, resource limitation could be a major concern in project execution. A restricted pool of resources with the desired technical experience makes it even more difficult to execute the work arrangement and meet deadlines. At the product development stage, participating in cross-functional groups becomes a difficult task for the project manager. Typically, team members also work on multiple events. The skills of team members in prioritization, awareness of the importance of tasks and effective communication become crucial for the productivity of the matrix organization. Lack of communication between team members, and between team members and their determined managers, will produce a chaotic situation at regular intervals during a project.

As companies face continuous changes in customer wants and regulatory, quality and safety needs, changes and updates to business processes become an exhausting task to accomplish. Often, project managers fall into an extremely difficult situation with non-routine processes. Senior management support in establishing clear business processes can help the project manager and project team achieve the project goal.

Managing cultural variations at regular intervals within the team, at regular intervals within the host companies and on the client side can be a challenge that the project manager encounters frequently. Managing customers adds another layer of challenges in management that involve cross-company collaboration and contract manufacturing organizations (CMOS). Ineffective management of client desires will cause scope to drift, increasing the project budget and causing delays. Establishing customer expectations in alignment with scope at the start of the method helps satisfy buyers. The contracting authority acts because of the face of the host company vis-à-vis the client and vice versa. This places project management in an extremely difficult situation when the client’s expectations do not match the guarantees offered by the host company in accordance with the agreement. Working with the client to develop a transparent scope definition in the early stages of the project is the desired approach to avoid confusion.

Drug and API manufacturers face problems with impurities in drugs, whether during manufacturing or storage. So, to counter this problem, reference standards for pharmaceutical impurities are available in the pharmaceutical market. These impurity reference standards also act as precursors for various components.

VEEPRHO is a global manufacturer and supplier of impurity reference standards for the pharmaceutical trade. We tend to be directly involved in the analysis, development and supply of synthesized impurities, metabolites, intermediates and APIs with custom synthesis. The VEEPRHO specialization includes:

  • Isolation of impurities from API or drug product by preceding HPLC.
  • Synthesis of impurities/metabolites.
  • Intermediates and Active Pharmaceutical Ingredients

Our aim is to produce vital goods needed within the pharmaceutical industry in a very fast manner. High laws, workability of products, as well as the constant discovery of scientific impurities/metabolites, occupy the United States, and we are committed to providing according to your desires, even providing personalized synthesis.

References

  • International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). (2012). The Pharmaceutical Industry and Global Health: Facts and Figures 2012 Retrieved March 1, 2014 from http://ifpma.org
  • Lichtenberg, Frank R. (2008). Have new cardiovascular drugs reduced hospitalizations? Data drawn from country-level longitudinal data on 20 OECD countries, 1995-2003. Retrieved March 1, 2014, from http://www.nber.org/papers/w14008
  • US Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC), Division of Bacterial Diseases (DBD). (1998). Heliobacter pylori and peptic ulcer. Retrieved March 1, 2014, from http://www.cdc.gov/ulcer